144 related articles for article (PubMed ID: 31488558)
1. 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.
Gackowski D; Gawronski M; Kerr C; Radivoyevitch T; Zarakowska E; Starczak M; Abakir A; Ruzov A; Maciejewski JP; Olinski R
Haematologica; 2020 May; 105(5):e213-e215. PubMed ID: 31488558
[No Abstract] [Full Text] [Related]
2. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
3. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
[TBL] [Abstract][Full Text] [Related]
4. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
6. Does
Song J; Moscinski L; Zhang H; Zhang X; Hussaini M
Cancer Genomics Proteomics; 2019; 16(1):91-98. PubMed ID: 30587503
[TBL] [Abstract][Full Text] [Related]
7. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.
Komrokji R; Volpe V; Chan O; Al Ali N; Swoboda D; Kuykendall A; Padron E; Sallman DA
Blood; 2021 Sep; 138(11):989-992. PubMed ID: 34036300
[No Abstract] [Full Text] [Related]
8. The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T
Pathobiology; 2019; 86(1):24-29. PubMed ID: 29791902
[TBL] [Abstract][Full Text] [Related]
9. Letter to the Editor regarding the article "Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis".
Yang T; Wang L; Zhang Y
Crit Rev Oncol Hematol; 2021 Jun; 162():103295. PubMed ID: 33992800
[No Abstract] [Full Text] [Related]
10. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
11.
Mangaonkar AA; Lasho TL; Finke C; Ketterling RP; Reichard KK; McCullough K; Gangat N; Al-Kali A; Begna KH; Hogan WH; Litzow MR; Alkhateeb H; Shah M; Pardanani A; Tefferi A; Al Ali NH; Talati C; Sallman D; Padron E; Komrokji R; Patnaik MM
Haematologica; 2022 May; 107(5):1189-1192. PubMed ID: 35142154
[No Abstract] [Full Text] [Related]
12. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
13. Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.
Song J; Hussaini M; Qin D; Zhang X; Shao H; Zhang L; Gajzer D; Basra P; Moscinski L; Zhang H
Am J Clin Pathol; 2020 Jun; 154(1):48-56. PubMed ID: 32112088
[TBL] [Abstract][Full Text] [Related]
14. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
[TBL] [Abstract][Full Text] [Related]
15. Clonal shifts in MDS - from SF3B1 to EZH2.
Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
[No Abstract] [Full Text] [Related]
16. Necrotizing myopathy associated with TET2-mutated myelodysplastic syndrome.
Dietrich T; de Mornac D; Garnier A; Espitia A; Néel A; Normand A; Toquet C; Agard C
QJM; 2022 Sep; 115(9):633-634. PubMed ID: 35689623
[No Abstract] [Full Text] [Related]
17. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.
Moyo TK; Savona MR
Curr Hematol Malig Rep; 2016 Dec; 11(6):441-448. PubMed ID: 27734261
[TBL] [Abstract][Full Text] [Related]
18. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
19. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.
Singh S; Ahmed D; Dolatshad H; Tatwavedi D; Schulze U; Sanchi A; Ryley S; Dhir A; Carpenter L; Watt SM; Roberts DJ; Abdel-Aal AM; Sayed SK; Mohamed SA; Schuh A; Vyas P; Killick S; Kotini AG; Papapetrou EP; Wiseman DH; Pellagatti A; Boultwood J
Leukemia; 2020 Sep; 34(9):2525-2530. PubMed ID: 32076118
[No Abstract] [Full Text] [Related]
20. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
Drusbosky LM; Cogle CR
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
